| Project/Area Number |
18K08026
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 53020:Cardiology-related
|
|---|
| Research Institution | Chiba University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
眞鍋 一郎 千葉大学, 大学院医学研究院, 教授 (70359628)
|
|---|
| Project Period (FY) |
2018-04-01 – 2021-03-31
|
| Project Status |
Completed (Fiscal Year 2020)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2020: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 心不全 / トランスクリプトーム解析 / DPP-4 / バイオマーカー / 心臓保護活性物質 |
|---|
| Outline of Final Research Achievements |
We previously confirmed that DPP-4 inhibition has beneficial effects on the hearts after myocardial infarction (MI) and elucidated novel mechanisms underlying the DPP-4 inhibition-mediated cardioprotective effects. DPP-4 inhibitors are newly available drugs for diabetes mellitus. DPP-4 is a serine protease which cleaves a dipeptide from the N-terminus of incretin. It has been reported that DPP-4 degrades and inactivates many other substrates other than incretin. Interestingly, G-CSF and erythropoietin, which have cardioprotective effects on heart failure, are also reported to be substrates of DPP-4. Therefore, we planned to explore novel cardioprotective agents by using substrates of DPP-4 whose expressions change in case of heart failure. We prepared enough hearts and blood samples from mice models of heart failure. And we elucidated the mechanisms of anti-fibrotic effects by DPP-4 inhibition in heart failure.
|
| Academic Significance and Societal Importance of the Research Achievements |
わが国の心不全患者数は年々増加しているが、この30年間で治療ガイドラインに挙げられている治療薬や治療効果に大きな変化はみられていない。患者の自覚症状や生命予後をこれまで以上に改善する画期的な新規治療薬の開発が待たれる。また、心不全の早期診断・早期治療により重症化に至らぬよう早い段階から心不全の進行を抑えることも必要であるが、心不全の早期診断バイオマーカーはこの10年間で新たなものは出現していない。したがってこれまでとは別の角度から心不全の病態解明にアプローチし、新規治療薬や診断バイオマーカーとなりうる標的候補を探索する必要がある。
|
